NEXUS AG: Further significant increase in sales and earnings in first half-year 2019

Development of Group Sales - NEXUS AG
(PresseBox) ( Donaueschingen, )
The hospital software specialist NEXUS AG increased its sales by around 8 % and its EBIT by around 13 % in the first half of 2019. The NEXUS Group therefore continued its long-standing positive sales and earnings performance.

Sales climbed by 8.2 % from KEUR 64,446 (6M-2018) to KEUR 69,708 in the first half of 2019. Consolidated EBIT improved by 13.4 % to KEUR 7,488 (6M-2018: KEUR 6,605). EBITA climbed by 12.9 % from KEUR 8,194 (6M-2018) to KEUR 9,247. EBITDA rose by 25.6 % (adjusted for IFRS 16
effect: 8.7 %) to KEUR 15,417 (adjusted for IFRS 16 effect: KEUR 13,340) (6M-2018: KEUR 12,276). Consolidated net income is up by 2.6 % at KEUR 5,346 in the first half of 2019 after KEUR 5,212.

Operating cash amounted to KEUR 28,871 after the strong prior-year figure (6M-2018: KEUR 18,268). NEXUS AG had cash funds including current financial assets of KEUR 36,432 as of 30 June 2019 (30 June 2018: KEUR 25,129). A dividend of KEUR 2,676 (2018: KEUR 2,519) was paid to our stockholders in 2019. Earnings per share amounted to EUR 0.27 in the first half of the year (previous year: EUR 0.32).

NEXUS AG had equity of KEUR 109,081 as of 30 June 2019 (31 December 2018: KEUR 108,325). NEXUS AG therefore has a consistently healthy statement of financial position and sufficient capital to continue financing its European growth strategy.

The detailed Half-Year Report can be found on our homepage at:

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to